These results indicate a possible opportunity to develop therapeutic drugs to disrupt methionine metabolism by targeting MARylation site of MAT2A or stabilizing SIRT4 expression for HCC treatment. The gene discussed is SIRT4; the disease is hepatocellular carcinoma.